Clinical R&D Lab To Scoop Up Pharma Testing Co. For $800M
Charles River provides research and development services to pharmaceutical and biotechnology companies and will be able to expand its research capabilities with the acquisition, the company said in a statement. The deal is expected to close in the second quarter of 2018 subject to regulatory approval.
“In addition to meeting our disciplined acquisition criteria, MPI is an exceptional strategic fit for Charles River because...
To view the full article, register now.